Mathematical modelling of hepatitis C treatment for injecting drug users

Journal of Theoretical Biology

Volumn 274, Issue 1, 2011, Pages 58-66

  Martin, Natasha K ^a,b   Vickerman, Peter ^a,b   Hickman, Matthew ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antiviral treatment; HCV; IDUs; Liver disease; Mathematical model

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

DISEASE PREVALENCE; DISEASE TRANSMISSION; DISEASE TREATMENT; DRUG USER; HEALTH RISK; HEPATITIS; NUMERICAL MODEL; POLICY IMPLEMENTATION; PUBLIC HEALTH;

ARTICLE; HEPATITIS C; IMMUNITY; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MATHEMATICAL MODEL; MORTALITY; PREVALENCE; PRIORITY JOURNAL; REINFECTION; SENSITIVITY ANALYSIS; SIMULATION; TREATMENT DURATION; VIRUS TRANSMISSION;

COMPUTER SIMULATION; DRUG USERS; HEPATITIS C; HUMANS; INJECTIONS; MODELS, BIOLOGICAL; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS;

HEPATITIS C VIRUS;

EID: 79251532744     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2010.12.041     Document Type: Article

References (32)

1. ACMD. 2009. The primary prevention of Hepatitis C among injecting drug users. Technical Report.
2. Blower S.M., Gershengorn H.B., Grant R.M. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000, 287(5453):650-654.
3. Booth J.C.L., O'Grady J., Neuberger J. Clinical guidelines on the management of Hepatitis C. Gut 2001, 49(Suppl. 1):I1-I21.
4. ECMDDA, 2004. Hepatitis C and injecting drug use: impact, costs and policy options. Office for Official Publications of the European Communities, Luxembourg.
5. Foster G.R. Injecting drug users with chronic hepatitis C: should they be offered antiviral therapy?. Addiction 2008, 103(9):1412-1413.
6. Granich R.M., Gilks C.F., Dye C., De Cock K.M., Williams B.G. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. The Lancet 2009, 373(9657):48-57.
7. Grebely J., Conway B., Raffa J., Lai C., Krajden M., Tyndall M.W. Uptake of hepatitis C virus (HCV) treatment among injection drug users (IDUS) in Vancouver, Canada. Journal of Hepatology 2006, 44(Suppl. 2):S214-S215.
8. Grebely J., Genoway K., Khara M., Duncan F., Viljoen M., Elliott D., Raffa J.D., DeVlaming S., Conway B. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. International Journal of Drug Policy 2007, 18(5):437-443.
9. Hahn J.A., Page-Shafer K., Lum P.J., Bourgois P., Stein E., Evans J.L., Busch M.P., Tobler L.H., Phelps B., Moss A.R. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. The Journal of Infectious Diseases 2002, 186(11):1558-1564.
10. Hellard M., Sacks-Davis R., Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clinical Infectious Diseases 2009, 49:561-573.
11. Hickman M., Hope V., Brady T., Madden P., Jones S., Honor S., Holloway G., Ncube F., Parry J. Hepatitis C virus (HCV) prevalence and injecting risk behaviour in multiple sites in England in 2004. Journal of Viral Hepatitis 2007, 14(9):645-652.
12. Hickman M., Hope V., Coleman B., Parry J., Telfer M., Twigger J., Irish C., Macleod J., Annett H. Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. Journal of Public Health (Oxford) 2009, 31(3):374-382.
13. Judd A., Hickman M., Jones S., McDonald T., Parry J.V., Stimson G.V., Hall A.J. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. British Medical Journal 2005, 330(7481):24-25.
14. Klevens, M., Jiles, R., Daniels, D., 2010. Distribution of reported hepatitis C genotypes in sites conducting enhanced hepatitis surveillance, 2009. In: 59th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010).
15. Litwin A.H., Harris K.A., Nahvi S., Zamor P.J., Soloway I.J., Tenore P.L., Kaswan D., Gourevitch M.N., Arnsten J.H. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. Journal of Substance Abuse Treatment 2009, 37(1):32-40.
16. Martin, N.K., Vickerman, P., Foster, G.R., Hutchinson, S.J., Goldberg, D.J., Hickman, M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modelling analysis of its prevention utility. Journal of Hepatology, in press, doi:. http://10.1016/j.jhep.2010.08.029.
17. May R.M. Thresholds and breakpoints in ecosystems with a multiplicity of stable states. Nature 1977, 269(5628):471-477.
18. McHutchison J.G., Manns M.P., Muir A.J. PROVE3 final results and 1-year durability of SVR with telaprevir-based regimen in hepatitis C genotype 1-infected patients with prior non-response. Hepatology 2009, 50:66A.
19. Mehta S.H., Cox A., Hoover D.R., Wang X., Mao Q., Ray S., Strathdee S.A., Vlahov D., Thomas D.L. Protection against persistence of hepatitis C. The Lancet 2002, 359(9316):1478-1483.
20. Micallef J.M., Kaldor J.M., Dore G.J. Spontaneous viral clearance following hepatitis C infection: a systematic review of longitudinal studies. Journal of Viral Hepatitis 2006, 13:34-41.
21. NICE. 2000. Inteferon alfa (pegylated and non-pegylated) and riabirin for the treatment of chronic hepatitis C.
22. NICE. 2006. Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C.
23. NIH. 2002. Management of hepatitis C. NIH Consensus Statement.
24. Nordt C., Stohler R. Incidence of heroin use in Zurich, Switzerland: a treatment case register analysis. The Lancet 2006, 367(9525):1830-1834.
25. Page-Shafer K., Pappalardo B.L., Tobler L.H., Phelphs B.H., Edlin B.R., Moss A.R., Wright T.L., Wright D.J., O'Brien T.R., Caglioti S., Busch M.P. Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. Journal of Clinical Microbiology 2008, 46(2):499-506.
26. Palmateer, N., Kimber, J., Hickman, M., Hutchinson, S.J., Rhodes, T., Goldberg, D.J., 2010. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and HIV transmission among injecting drug users: a review of reviews. Addiction 105 (5), 844-859.
27. Reimer J., Schulte B., Castells X., Schafer I., Polywka S., Hedrich D., Wiessing L., Haasen C., Backmund M., Krausz M. Guidelines for the treatment of hepatitis C virus infection in injection drug users: status Quo in the European union countries. Clinical Infectious Diseases 2005, 40(s5):S373-S378.
28. Seal K.H., Kral A.H., Lorvick J., Gee L., Tsui J.I., Edlin B.R. Among injection drug users, interest is high, but access low to HCV antiviral therapy. Journal of General Internal Medicine 2005, 20(Suppl. 1):171.
29. Seeff L.B. The history of the "natural history" of hepatitis C (1968-2009). Liver International 2009, 29(s1):89-99.
30. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. The Lancet Infectious Diseases 2005, 5(9):558-567.
31. Shepherd J., Jones J., Hartwell D., Davidson P., Price A., Waugh N. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technology Assessment 2007, 11(11):1-224.
32. Sweeting M.J., De Angelis D., Ades A.E., Hickman M. Estimating the prevalence of ex-injecting drug use in the population. Statistical Methods in Medical Research 2009, 18(4):381-395.